A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis

References

• Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6(2):214–220.
   PubMed Web of Science ®Google Scholar
• Merlini G. Systemic amyloidosis: are we moving ahead? Neth J Med.The Netherlands Journal of Medicine. 2004;62(4):104–105.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol. 2013;9(10):574–586.
   PubMed Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. In: Frank MM, Austen KF, Claman HN, et al., editors. Samter’s Immunologic Diseases. Fifth ed. Boston: Little, Brown and Company; 1994. p. 637–655.
   Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.
   PubMed Web of Science ®Google Scholar
• Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003;17:909–927.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 2012;126(10):1286–1300.
   PubMed Web of Science ®Google Scholar
• Pinney JH, Whelan CJ, Petrie A, et al. Senile Systemic Amyloidosis: clinical Features at Presentation and Outcome. J Am Heart Ass. 2013;2:2.
   Web of Science ®Google Scholar
• Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004;30:178–181.
   PubMed Web of Science ®Google Scholar
• Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723–1777. .
   PubMed Web of Science ®Google Scholar
• Maurer MS. Noninvasive Identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015;128(12):17.
   Web of Science ®Google Scholar
• Cornwell GG 3rd, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75:618–623.
   PubMed Web of Science ®Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239. .
   PubMed Web of Science ®Google Scholar
• Castano A, Manson DK, Maurer MS, et al. Transthyretin cardiac amyloidosis in older adults: optimizing cardiac imaging to the corresponding diagnostic and management goal. Curr Cardiovasc Risk Rep. 2017;11:11.
   Web of Science ®Google Scholar
• Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. .
   PubMed Web of Science ®Google Scholar
• Carr AS, Pelayo-Negro AL, Evans MR, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol NeurosurgJournal of Neurology, Neurosurgery & Psychiatry. 2016;87(6):620–627. .
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 20132006;3696(92):819–829. .
   Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat.Human Mutation. 2014;35(9):E2403–E2412. .
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Alexander AA, Tagoe C, et al. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans African–Americans. Amyloid. 2015;22(3):171–174. .
   PubMed Web of Science ®Google Scholar
• Castano A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163–178. .
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112(13):2047–2060.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466–477. .
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–1904. .
   PubMed Web of Science ®Google Scholar
• Murphy L, Falk RH. Left atrial kinetic energy in AL amyloidosis: can it detect early dysfunction? Am J Cardiol. 2000;86(2):244–246.
   PubMed Web of Science ®Google Scholar
• Modesto KM, Dispenzieri A, Cauduro SA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. EurEuropean Heart J.Journal. 2005;26(2):173–179. .
   PubMed Web of Science ®Google Scholar
• Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420–2426. .
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol. 2019;73(13):1733–1734.
   PubMed Web of Science ®Google Scholar
• Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439–1447.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond).Clinical Medicine. 2018;18(Suppl 2):s30–s35.
   PubMed Web of Science ®Google Scholar
• Falk RH, Quarta CC. Echocardiography in cardiac amyloidosis. Heart Fail Rev. 2015;20(2):125–131.
   PubMed Web of Science ®Google Scholar
• Porciani MC, Lilli A, Perfetto F, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16(2):63–70.
   PubMed Web of Science ®Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–193.
   PubMed Web of Science ®Google Scholar
• Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579.
   PubMed Web of Science ®Google Scholar
• McDonald RJ, Levine D, Weinreb J, et al. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology. 2018;289(2):517–534.
   PubMed Web of Science ®Google Scholar
• McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR Imaging. Radiology 2015;275(3):772–782.
   PubMed Web of Science ®Google Scholar
• Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276(1):228–232.
   PubMed Web of Science ®Google Scholar
• Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26(3):807–815.
   PubMed Web of Science ®Google Scholar
• Murata N, Gonzalez-Cuyar LF, Murata K, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51(7):447–453.
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–497.
   PubMed Web of Science ®Google Scholar
• Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–165.
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic al amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2012;6(1):34-39.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–819.
   PubMed Web of Science ®Google Scholar
• Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. Jacc Cardiovasc Imaging. 2021;14(1):189–199.
   PubMed Web of Science ®Google Scholar
• Ferreira VM, Piechnik SK, Robson MD, et al. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping. J Thorac Imaging. 2014;29(3):147–154.
   PubMed Web of Science ®Google Scholar
• Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919–2931.
   PubMed Web of Science ®Google Scholar
• Ali A, Turner DA, Rosenbush SW, et al. Bone scintigram in cardiac amyloidosis: a case report. Clin Nucl Med. 1981;6(3):105–108.
   PubMedGoogle Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Guidalotti P, Salvi F, et al. Usefulness of Tc-99m-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51(15):1509–1510.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470–478.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castano A, Pozniakoff T, et al. 99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.
   PubMed Web of Science ®Google Scholar
• Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5(7):755–758.
   PubMed Web of Science ®Google Scholar
• Glaudemans AW, Van Rheenen RW, Van Den Berg MP, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014;21(1):35–44.
   PubMed Web of Science ®Google Scholar
• Castano A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2595–2597.
   PubMedGoogle Scholar
• Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–1690.
   PubMed Web of Science ®Google Scholar
• Falk RH, Lee VW, Rubinow A, et al. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983;51(5):826–830.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Quigley A-M, Page J, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardio Imag. 2014;15(11):1289–1298.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344–1350.
   PubMed Web of Science ®Google Scholar
• Cappelli F, Gallini C, Costanzo EN, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: an underestimated phenomenon. Int J Cardiol. 2018;254:346–350.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78–84.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–1369.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786–1791.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Hawkins PN. V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(18):1769.
   PubMedGoogle Scholar